Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function

被引：0
|
作者：
Ebina, M.
Kimura, Y.
Ohta, H.
Hisata, S.
Tamada, T.
Nukiwa, T.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3988
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    [J]. INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [2] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [3] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [4] ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS (IPF) DEPENDS ON THE PREDICTIVE EQUATION USED IN PULMONARY FUNCTION TESTING
    Burgess, Andrew
    Goon, Ken
    Attia, John
    Palazzi, Kerrin
    Brannan, John
    Grainge, Christopher
    [J]. RESPIROLOGY, 2017, 22 : 46 - 46
  • [5] Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent
    Kishaba, T.
    Nagano, H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
    Stornelli, Silvia Romana
    Lacedonia, Donato
    Scioscia, Giulia
    Simone, Filomena
    Lepore, Giorgia
    Sabato, Roberto
    Giganti, Giulio
    Ciliberti, Gianluca
    Barbaro, Maria Pia Foschino
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [7] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    [J]. PLOS ONE, 2024, 19 (06):
  • [8] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [9] An Evaluation of 116 patients with Idiopathic Pulmonary Fibrosis (IPF) commenced on anti-fibrotic treatment therapies (Pirfenidone and Nintedanib) from Jan 2019 to June 2021
    Bowen, B. R.
    Henry, M. T.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 5) : 162 - 162
  • [10] Ptpn11 Is A Novel Anti-Fibrotic Gene In Idiopathic Pulmonary Fibrosis
    Tzouvelekis, A.
    Cardenas, C. Lacks Lino
    Yu, G.
    Sakamoto, K.
    DeIuliis, J.
    Wyllie, A.
    Ahangari, F.
    Woolard, T.
    Heather, L.
    Herazo-Maya, J. D.
    Kaminski, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
12345